ArticleHeliyon2025
Exploration of metastasis-related signatures in osteosarcoma based on tumor microenvironment by integrated bioinformatic analysis.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integration of Single-cell Sequencing Analysis Reveals Disulfidptosis Related Molecular Subtype and Novel Prognosis System for Osteosarcoma.Current medicinal chemistry · 2026Article
- Identification of endothelial INSR as an osteosarcoma-related biomarker and therapeutic target based on weighted gene co-expression network analysis.Discover oncology · 2025Article
- Exploratory Analysis of Molecular Subtypes in Early-Stage Osteosarcoma: Identifying Resistance and Optimizing Therapy.Cancers · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The present study aims to explore the metastasis-related signatures in connection with tumor microenvironment (TME), revealing new molecular targets promising in improving osteosarcoma (OS) patients' outcomes. Methods: The high-throughput sequencing data was downloaded from the TARGET database and performed the ESTIMATE algorithm. Metastasis-related information was obtained from the GSE21257 dataset. Differentially expressed genes (DEGs) associated with the stromal and immune cell infiltration patterns were identified. DEGs with similar biological functions were grouped into the same module by Gene Ontology (GO) analysis and MCODE analysis. Prognostic DEGs were selected in two datasets through survival analysis. Weighted gene co-expression network analysis (WGCNA) was performed to find metastasis-related modules and genes. RT-PCR was utilized to evaluate the expression of the key prognostic DEGs associated with metastasis in OS patients. Results: The median scores of the stromal and immune groups of OS samples were 58 and -416, and a total of 200 overlapping DEGs were identified. These DEGs basically played fundamental roles in immune response relevant GO terms and were clustered into 9 different modules. Among them, 24 metastasis-related DEGs were selected from the GSE21257 dataset which contains the stromal and immune cell infiltration patterns. Finally, IRF8, HLA-DMA, and HLA-DMB were proved to exhibit significant higher expression levels in cancerous tissues than in para-cancerous tissues for OS patients. Conclusion: We identified three principal genes as promising signatures for predicting the survival the prognosis of OS patients. Exploration of metastasis-related signatures in TME may be valuable for enhancing treatment strategies for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.